NVS Latest Headlines

VYMI vs. VIG vs. VYM: Which Vanguard Dividend ETF Pays You Most?

at www.tipranks.com (Wed, 1-Apr 7:24 AM)

Is Trump to blame for delayed drug launches in Europe

at seekingalpha.com (Tue, 31-Mar 12:28 PM)

Goldman Sachs Keeps Their Sell Rating on Novartis AG (NOVN)

at www.tipranks.com (Tue, 31-Mar 3:56 AM)

Teva gains approval of biosimilar of Amgen's Prolia

at seekingalpha.com (Mon, 30-Mar 11:01 AM)

Citi Reaffirms Their Buy Rating on Novartis AG (NOVN)

at www.tipranks.com (Mon, 30-Mar 9:16 AM)

Buy Rating on Novartis: Durable Growth from New Therapies and Late-Stage Pipeline Offsets Near-Term Margin Pressure and LOE Risk

at www.tipranks.com (Mon, 30-Mar 6:25 AM)

Deutsche Bank Keeps Their Buy Rating on Novartis AG (NOVN)

at www.tipranks.com (Mon, 30-Mar 5:25 AM)

Novartis: Excellergy Deal Adds Long-Dated Pipeline Risk Amid LOE Headwinds, Supporting Sell Rating

at www.tipranks.com (Fri, 27-Mar 10:05 AM)

Novartis AG (NOVN) Receives a Hold from Barclays

at www.tipranks.com (Fri, 27-Mar 5:45 AM)

Novartis (NVS) Stock Rises on $2B Excellergy Acquisition to Expand Allergy Portfolio

at www.tipranks.com (Fri, 27-Mar 5:37 AM)

Novartis to buy Excellergy for up to $2B to boost allergy portfolio

at seekingalpha.com (Fri, 27-Mar 3:43 AM)

Novartis Aims for Multi-Billion-Dollar Growth with Avidity Biosciences Acquisition: Late-Stage Pipeline Takes Center Stage

Market Chameleon (Fri, 27-Feb 9:23 AM)

Bullish On NVS? You Might Want To Consider This Credit Put Spread Expiring in 12 Days

Market Chameleon (Wed, 4-Feb 10:20 AM)